Neurogene to Participate in Upcoming Investor Conferences
Neurogene to Participate in Upcoming Investor Conferences
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference
Format: Management will participate in a fireside chat and investor meetings
Date: Tuesday, November 10 at 10:30 a.m. ET
Stifel 2026 Healthcare Conference
Format: Management will participate in a fireside chat and investor meetings
Date: Wednesday, November 11 at 10:40 a.m. ET
Live webcasts of the fireside chats will be accessible from the Investor Relations section of Neurogene’s website under Events & Presentations, where replays of the events will also be available for a limited time.
About Neurogene
Neurogene (Nasdaq: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn.
Media Contact:
Mike Devine
Executive Director, Corporate Communications
michael.devine@neurogene.com
Investor Contact:
Lina Li
Executive Director, Investor Relations
lina.li@neurogene.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103409653/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

Retirees: 5 Reasons to Consider Index Funds and ETFs

3 of the Best Core Stocks to Own

This Newly Undervalued Stock Has Plenty of Growth Ahead

4 Growth Stocks to Buy While They’re Still Undervalued
